Outcome variable | Number of studies | Sample size | Number of events | Test of association | Test of heterogeneity |
---|
ORa,d | 95% CI | Model | I2% | p-value |
---|
Abdominal obesity | 9 | 18,121 | 4655b | 1.00 | 0.88–1.12 | Fixed | 3.5 | 0.40 |
Low HDL-C | 8 | 17,874 | 4148b | 0.94 | 0.78–1.14 | Random | 58.1 | 0.01 |
Hyper- triglyceridemia | 8 | 17,874 | 3954b | 1.09 | 0.98–1.22 | Fixed | 0.0 | 0.73 |
HTN | 12 | 77,194 | 13,496c | 1.17 | 1.10–1.25 | Fixed | 36.4 | 0.12 |
Hyperglycemia | 8 | 17,876 | 4651b | 1.21 | 1.01–1.44 | Random | 54.0 | 0.02 |
MetS | 11 | 42,978 | 4524b | 1.13 | 1.03–1.25 | Random | 54.8 | 0.02 |
- HDL-C high density lipoprotein-cholesterol, HTN hypertension, MetS metabolic syndrome, OR odds ratio, CI confidence interval
- *HR, Hazard ratio; OR, Odds ratio; Q test, Cochran test
- aCohort or cross-sectional study
- bParticipants with abdominal obesity, low-HDL-C, hyper-triglyceridemia, hyperglycemia and MetS had not been stated in three studies
- cParticipants with HTN had not been stated in five studies
- d The odds ratio is for the highest pro-inflammatory diet (the highest DII) versus the highest anti-inflammatory diet (the lowest DII)
- eCase–control or cross-sectional study